Soleno Therapeutics Announces Peer-Reviewed Publication of Data Comparing DCCR Treatment to the Natural History of Prader-Willi Syndrome

REDWOOD CITY, Calif., April 30, 2024 -- Soleno Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the...

Related Keywords

United States ,Jennifer Miller ,Brian Ritchie ,Shawn Mccandless ,Prader Willi Syndrome Association United States ,Globenewswire Inc ,Research Programs ,Securities Exchange ,Soleno Therapeutics Inc ,Lifesci Advisors ,Company Phase ,Foundation For Prader Willi Research ,Diazoxide Choline ,History Study ,Hyperphagia Questionnaire ,Clinical Trials ,Prader Willi Syndrome Profile ,Principal Investigators ,Prader Willi Research ,Orphan Drug Designation ,Fast Track ,Breakthrough Designations ,Soleno Therapeutics ,Securities Exchange Act ,Sci Advisors ,Markets ,